Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amorcyte has completed the Phase I clinical trial of its lead product, AMR-001 - an autologous stem cell product for the treatment of damaged heart muscle following acute myocardial infarction.
Subscribe to our email newsletter
Arshed Quyyumi, principal investigator of the trial, said: “This trial has demonstrated proof of principle for this type of cell-based therapy. We have shown that it is possible to take progenitor stem cells harvested and extracted from a patient’s bone marrow shortly after a heart attack and deliver these cells back into the patient’s heart with the intent of repairing the damaged heart muscle. We eagerly anticipate beginning a Phase II trial.”